At the forefront of new diabetes research is the immunoproteasome, a specialized form of proteasome responsible for regulating sugar and fat metabolism, as well as insulin-producing beta cells. A recent review in the journal Genes & Diseases (2026) highlights the pivotal role of this cellular machinery.
Two Types of Diabetes, Two Mechanisms
The immunoproteasome functions differently depending on the type of diabetes. In Type 1 diabetes, it accelerates the destruction of beta cells. Conversely, in Type 2 diabetes, it serves as a protective factor against chronic inflammation and cellular stress. Research has also revealed the involvement of the immunoproteasome in severe comorbidities, such as cardiovascular issues, kidney damage, and retinal complications. Selective inhibitors are emerging as a promising new class of therapies that extend beyond mere blood sugar control.
Beta Cells: Not Passive Victims
Recent studies from Indiana University published in late June 2026 in Science Translational Medicine offer new insights into the behavior of beta cells in Type 1 diabetes. Healthy beta cells respond to specific immune stimuli with an outbreak of reactive oxygen species (ROS), which activates antiviral protective mechanisms. However, this protection is conspicuously absent in Type 1 diabetes.
Researchers also discovered defects in autophagy flux—a crucial cellular cleansing process—occurring before blood sugar levels rise. Therefore, beta cells are not merely passive victims; they actively participate in the disease progression.
Immunotherapy and Cell Transplantation: New Milestones
Teplizumab, an immunotherapy, can delay the onset of Type 1 diabetes by up to three years, provided treatment begins before the first symptoms appear. For early detection, blood tests for immune activity are essential. In England and Wales, Teplizumab is now accessible through the NHS, underscoring the need for timely diagnosis.
Another breakthrough is on the horizon with islet cell transplantation. The University of Chicago Medicine presented Phase 1 study results in June 2026, revealing that all twelve participants achieved insulin independence post-transplant without rejection reactions. The Anti-CD40L antibody from Eledon Pharmaceuticals allows for more targeted immunosuppression compared to traditional medications.
Precision Medicine and Organ Protection
The CEDA Annual Congress in late June 2026 in Düsseldorf emphasized the importance of differentiated diabetes consideration. Experts are advocating for precision diabetes management to develop subtype-specific therapies. Approximately 70% of Type 2 diabetics suffer from metabolically associated steatotic liver disease (MASLD), making this need especially pressing.
In the realm of kidney protection, SGLT2 inhibitors like Dapagliflozin and Empagliflozin have become standard treatments. The American Diabetes Association (ADA) recommends these agents as cornerstones for protecting the heart and kidneys. In late June 2026, a new SGLT2 inhibitor, Enavogliflozin, was launched in Indonesia, especially validated for Asian populations.
The Downsides of Progress
While Teplizumab and islet cell transplantation with Tegoprubart show promise—achieving insulin independence in all participants—patients still face significant burdens. The RKI study “Health 65+” (data up to 2024) indicates that older individuals with Type 2 diabetes experience higher rates of depression and loneliness than non-diabetics.
Furthermore, side effects of modern incretin-based therapies (GLP-1 receptor agonists) are under scrutiny. Analysis of nearly 877,000 patients in JAMA Otolaryngology (2026) suggests a slight increase in risks for smell and taste disorders. A study in Lancet Diabetes & Endocrinology (July 2026) demonstrates that discontinuing such therapies can potentially lead to rapid weight gain. Nevertheless, the authors argue that the benefits of repeated weight reduction outweigh the risks associated with the yo-yo effect on metabolism and cardiovascular health.
